Investment Teaser

AI-driven diagnosis of rare disease

SAVENTIC
Health

*Supporting **Patients**, Doctors, Clinics with Diagnosis to facilitate access to treatment or clinical trials*

Our mission is to create and implement AI-driven algorithms supporting the diagnosis of rare diseases

SAVENTIC
Health

Who we are

Med-tech combining **AI algorithms, implementation platforms** and processes **to support doctors, patients and medical clinics in diagnosing rare diseases.**

- In 2023 we secured 1m EUR in revenue, expanded clients' base, started first contracts in Germany, France and Brazil
- In 2024 we enter the Canadian market and expand presence in LATAM and EU

We increase access to treatments and clinical trials for our global customers

Takeda   RECORDATI   IPSEN Innovation for patient care   Bristol Myers Squibb   SANOFI

NOVARTIS   EUSAPharma   AstraZeneca   Pfizer   BeiGene

Only 1 out of 8

patients with RDs is diagnosed & duly treated, many remain undiagnosed. Resulting in worse symptoms, higher risk of mortality & overall lower quality of life

Rare Diseases diagnosis is a major problem in healthcare ecosystem

RDs affect worldwide up to

450m people

→ **that's 5-6% of population**

8000

RDs are known to exist today

→ **only 10% with treatment**

Diagnostic odyssey takes ca.

5 years

→ pharma cannot sell drugs, most cost **>$500k per year per patient.**

**Lack of tools,** which use big data to support doctors in **diagnostics**

→ **patients receive 2-3 misdiagnoses, see 8 physicians**

Market opportunity worth 13 billion USD in 2023 with 15% CAGR

Global rare disease digital diagnostics market 2023-2030 (mUSD)

TAM, SAM, SOM as of 2030 (mUSD)

CAGR = 15%

34 720
30 914
26 052
23 454
19 604
17 644
14 512
13 005

2023 2024 2025 2026 2027 2028 2029 2030

■ For clinical trials (developing orphan drugs)   ■ For treatment (exsting orphan drugs)

TAM
34,720 → Global market

SAM
7,649 → Total opportunities in targeted countries

SOM
c.400 → Estimated revenue

Source: own market sizing cross checked with BIS Research

Opportunity
of >1300

rare diseases with available treatment or under advanced development

The effectiveness of our products is **15-20x better than today's approach**

We provide results to pharma/biotech sector to save costs of diagnosis, clinical trials recruitment and increase revenue from the sale of drugs

Strong growth drivers, both short and long-term

FDA and EMA approved
760 orphan drugs
since the passage of the Orphan Drugs Act

Hope in the Pipeline

Currently, there are around
560 medicines
in advanced development for rare diseases (3 phase)

CB Insights identified
>100 companies
focused on curing RDs

In 2020, digital spending of
$10b by pharma

80% of know RDs are diagnosable

24% of hospitals

In OECD implemented digital solutions

Statistics provided in the Appendix

Saventic has unique competitive advantages, e.g. access to EHR

| | | | Product | | Operational & development focus | | | | | | |
Company	HQ	Raised (mUSD)	Platform for hospitals	Platform for patients	Clinical database	Use of EHRs	Focus on RDs	Global expansion	Diagnosis of RDs	Clinical trials	Developing drugs
SAVENTIC Health	🇵🇱	3	✓	✓	✓	✓	✓	✓	✓	✓	
AllStripes	🇺🇸	67		✓			✓	✓		✓	
healx	🇬🇧	70					✓	✓		✓	✓
mendelian	🇬🇧	0.7	✓		✓	✓	✓		✓		
volv	🇨🇭	n/a	✓				✓	✓	✓		
ada	🇩🇪	190		✓			✓		✓		

Saventic Health - AI-Tools:
AI algorithms, implementation platforms & innovative processes

SAVENTIC
Health

+ Workshops with KOLs

+ Recent publications, papers

+ Constant improvement (prospective implement.)

Medical Data

Database

Analysis

Structure & Label

Encrypt & Anonymize

NLP
Natural language processing

AI
Artificial Intelligence

30 Co-operating clinics

12M Patients in our database

50 AI-driven algorithms

in progress

Two comprehensive solutions

IMPLEMENTATION PLATFORMS
Free implementation

CE Medical Product class 1

1 SAVENTIC Med — Platform for Clinics

2 SAVENTIC Care — Platform for Patients

Users
- Medical clinics & doctors
- Patients & caregivers & doctors

Input data
- EHR (lab, radiology, and all descriptive data)
- Symptoms' questionnaire
- Medical documents (lab results, photos, etc.)

Implementation
- Local implementation at clinic
- Data encrypted & anonymized – GDPR compliant
- Online website application (example) – www.SaventicCare.com.br

Watch video: https://www.youtube.com/watch?v=qbd_HQ6Nnb8&t=23s   https://www.youtube.com/watch?v=Iz59b_NOd_U&t=105s

Our value proposition across the key stakeholders

SAVENTIC
Health

shorten diagnosis time &
increase efficacy

RARE DISEASE
PATIENTS

+   Quality of Life

reducing cost of diagnosis &
patient treatment

HEALTH CARE
SYSTEMS

+   Savings

increase patients' access
to treatments and clinical
trials

PHARMA / BIOTECH
INDUSTRY

+   Sales revenue

Business Model - SaaS

B2B
Subscription Fee

AI Platforms

PHARMA / BIOTECH INDUSTRY

SAVENTIC Health

CLINICS & PATIENTS

Provide Orphan Drugs

Identify Patients

Key Accomplishments

2023: 12 Clients in DE, PL, FR, BR

Nov. 23: 1 Million Euro Deal in DE

RD digital diagnostic market value:

$34.7 bn

Case study: 5 new patients with Fabry diagnosed & started treatment, lives saved, increased revenue from selling orphan drugs

SAVENTIC
Health

No chronic disease, nystagmus, dizziness, tinnitus, single focal lesion on MRI

Previous data + hypertrophic cardiomyopathy, right ear hearing loss

Previous data + hospitalization for chest pain.Suspected cardiac amyloidosis (finally negative)

Previous data + cardiomyopathy of mother, brother and sister. Transplantation of both kidneys of a brother

Saventic AI-algorithm implemented in one of hospitals , 52-year old patient with a very high % of Fabry disease

Patient referred for genetic tests and Fabry diagnosis confirmed. Subsequently, other family members referred for tests, 4 of them confirmed

April 2016   May 2016   January 2021   February 2021   March 2022   May 2022

**Algorithm would have indicated the patient if it had been implemented**

**6 years**

Patient & family diagnosed with Fabry

| 12% | 66% | 70% | 92% | 92% | diagnosed |

Algorithm - probability of Fabry disease

CONFIDENTIAL

Clients and potential clients

Poland / CEE region	Brazil	Germany / France	US/Canada
Recurring revenue	First clients	First clients	Negotiations

International expansion

Revenue & EBITDA in 2021-2028 (mEUR)

Legend: Revenue, EBITDA

Year	Revenue	EBITDA
2021	0,2	-1,9
2022	0,5	-0,8
2023	1,0	-0,9
2024	2,5	-1,9
2025	10,2	-5,3
2026	21,2	-4,8
2027	39,8	9,8
2028	68,8	34,1

2023 developments:

- Jan.23: 3 signed clients in PL

- Dec.23: 12 signed clients across PL, FR, BR & DE

- ~ 90% of revenues is from MRR, secured 1m EUR of revenue

- Dec 23 signed agreement with Alberta Health Services to screen 4.4 million patients (CA)

- Nov 23: signed customer project for 1 Mil. Euro in DE

Global expansion started in May 2022

SAVENTIC
Health

Germany / France
First clinics and pharma clients

USA/Canada
Signed contract with Alberta NHS, start 06/2024

Rest of Europe
Advanced talks with clients

Poland & CEE
R&D centre, recurring revenue, both platforms operational

We are expanding across different regions and signing global contracts with our clients

Brazil
First clinics and pharma clients

CONFIDENTIAL

We are raising 10 mEUR for strengthening value proposition and global expansion

Already committed (Series A): 5 mEUR
To date raised: 3 mEUR from VCs

R&D financed significantly by grants

➤ Global expansion with a focus on Americas, including US and Canada with both our platforms.

➤ Expansion into new segments of the market (value proposition opportunities), e.g. clinical trials in rare diseases, patients' monitoring in rare diseases (real world data), solutions for existing and new patients

➤ Development of new algorithms to cover all specialties and strengthening value position in hematology, metabolic storare, primary immune disorder, rheumatology, neurology, dermatology and cardiology.

➤ Built global recognition as the leader and one-stop-platform in rare diseases

➤ Improve and develop new technologies to obtain stronger competitive environment (algorithms efficacy)

CONFIDENTIAL

Our experienced & diverse team of 36 professionals

Szymon Piątkowski, CEO
- +12 years at PwC & EY with focus health consulting
- MA in finance & B.Sc. in computer engineering

Prof. Grzegorz Basak, MD, CMO
- +17 years Dep. of Hematology, Oncology & Internal Medicine
- Ph.D. in Molecular Medicine

Global

Szymon Piątkowski
CEO, Co-Founder

Prof. Grzegorz Basak, MD
CMO, Co-Founder

Joanna Jarmoc
Global BD Manager

Germany

Maciek Klein
Germany CM

Brazil

Henrique Malina
Brazil CM

Canada

Kim King
Canada CM

Poland/CEE

Karol Lis, MD
CEE CM

Marek Dudziński, MD
Medical Director

PhD Michał Dąbrowski
Tech Lead

## Business & operations

Medical Team

AI / Data Science / Programming

info@saventic.com
szymon.piatkowski@saventic.com

https://www.saventic.com/

SAVENTIC
Health

TOGETHER WE CAN DO MORE

Problem: Long and complex patient's pathway today

CONFIDENTIAL

Our Value added: Shorter patient's pathway, quicker diagnosis

GP

Specialist

Saventic AI

Blood tests

??

Biochem

Direct patient pathway

Correct Dx

Weeks ….

Months….

Our process to design the algorithm

1st Stage: Creating the model

- Data analysis (our database)
- Workshops with experts
- Features set creation
- Features extraction (NLP tools)
- Control group creation
- Scoring application (sensitivity, specificity)
- Records analysis by physicians
- Identifying patients with high risk of a RD
- Referring patients for diagnosis

2nd Stage: Updating the model

- Collecting data of patients referred for diagnosis
- Unsupervised methods usage
- Feature weights update
- Patients screening
- Records analysis by physicians
- Identifying patients with high risk of a RD
- Referring patients for diagnosis

3rd Stage: "Disease-like" model

- Data set of patients referred for diagnosis in (stage 1&2)
- ML disease-like classifier creation
- Patient screening
- Records analysis by physicians
- Identifying patients with high risk of a RD
- Referring patients for diagnosis

4th Stage: Final algorithm

The algorithm is ready for automatic implementation. Every quarter, we analyze patient data, and collect feedback from hospitals to which we have referred patients, in order to constantly improve the model

Saventic Health's Portfolio of AI algorithms

Rare Diseases

Blood and bone marrow
- Blood cancers (various including, mastocytosis and myelofibrosis)
- CTCL
- TTP
- PNH
- Castleman
- ITP
- HLH

Metabolic
- Gaucher Disease
- Fabry Disease
- Pompe Diseases
- HAE
- MPS 1
- MPS 2 (Hunter)
- MPS 3

Immune system
- Common variable immunodeficiency (CVID)
- Severe combined immunodeficiency (SCID)
- DiGeorge syndrome
- Chronic granulomatous disease (CGD)

Other
- Amyloidosis AL
- Amyloidosis ATTR
- Spasticity
- Hypercholesterolemia
- IPF*
- Lupus*
- Huntington's disease*

*in addition

Approx. 30 algorithms in our pipeline